| Biomarker ID | 708 |
| PMID | 21894431 |
| Year | 2011 |
| Biomarker | serum amyloid A (SAA) |
| Biomarker Basis | Concentration Based (μg/dl) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated (Healthy: 9.96±4.16 Vs without α2M deficiency: 54.7±44.5) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(SAA1):- TAK1 activates NF-kappaB by phosphorylation and activation of IKK complex, TRAF6 mediated NF-kB activation, Advanced glycosylation endproduct receptor signaling, Cytosolic sensors of pathogen-associated DNA, Folate metabolism |
| Experiment | healthy controls vs. PCa patients without α2M deficiency; |
| Type of Biomarker | Diagnostic |
| Cohort | 43 untreated adult men participated in this study, of whom 10 were healthy controls (mean age 62.8 years, range 52-70) and 33 were diagnosed with prostatic disease. Out of those with prostate cancer- Without α2M deficiency (n=23) and with α2M deficiency (n=10). |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.01 |
| Method Used | Western blot |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | SAA1 |